Disc Medicine Q1 2025 Earnings Report

Disc Medicine EPS Results

• Actual EPS: -$1.02
• Consensus EPS: -$0.99
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Disc Medicine Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Disc Medicine Announcement Details

• Quarter: Q1 2025
• Date: 5/7/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 7, 2025
• Conference Call Time: 8:00AM ET

Disc Medicine (NASDAQ:IRON) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapies for rare genetic diseases driven by oxidative stress and mitochondrial dysfunction. The company’s proprietary platform enables the rapid identification and optimization of compounds designed to restore cellular redox balance in underserved patient populations. Its lead programs target debilitating conditions such as Friedreich’s ataxia and Fanconi anemia, where dysregulated iron metabolism and mitochondrial injury are central to disease pathology.

Leveraging a combination of structure‐based design and phenotypic screening, Disc Medicine has advanced its lead candidate through IND‐enabling studies and into early human trials. Preclinical programs also include novel compounds aimed at neurodegenerative and mitochondrial disorders, reflecting the company’s commitment to expanding its pipeline across multiple indications with significant unmet medical need. In parallel, Disc Medicine maintains an active research collaboration network with leading academic institutions to validate novel therapeutic hypotheses.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine draws on deep expertise in redox biology and drug discovery. Since its inception, the company has secured strategic collaborations and licensing agreements that broaden its access to complementary technologies and accelerate its development timelines. Its teams operate from state‐of‐the‐art laboratories in the greater Boston area, supporting both in vitro and in vivo studies that underpin its clinical-stage assets.

The executive leadership team at Disc Medicine comprises seasoned biotech and pharmaceutical professionals with extensive experience in clinical development, regulatory affairs and commercial strategy. Together, they guide the company’s efforts to translate pioneering science into targeted therapies, with the aim of delivering meaningful treatment options to patients worldwide. Disc Medicine continues to expand its organizational capabilities, positioning itself for future growth across North America, Europe and Asia.